NO960049L - Fremstilling og stabilisering av celler - Google Patents

Fremstilling og stabilisering av celler

Info

Publication number
NO960049L
NO960049L NO960049A NO960049A NO960049L NO 960049 L NO960049 L NO 960049L NO 960049 A NO960049 A NO 960049A NO 960049 A NO960049 A NO 960049A NO 960049 L NO960049 L NO 960049L
Authority
NO
Norway
Prior art keywords
preparation
cells
stabilization
stabilized
stabilized cell
Prior art date
Application number
NO960049A
Other languages
English (en)
Norwegian (no)
Other versions
NO960049D0 (no
Inventor
Vivian Granger
David Barnett
John Tennison Reilly
Petra Susanne Maria Mayr
Shawn Patrick Fay
Original Assignee
North Gen Hospital Nhs Trust
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB939313962A external-priority patent/GB9313962D0/en
Priority claimed from GB9406698A external-priority patent/GB9406698D0/en
Application filed by North Gen Hospital Nhs Trust filed Critical North Gen Hospital Nhs Trust
Publication of NO960049D0 publication Critical patent/NO960049D0/no
Publication of NO960049L publication Critical patent/NO960049L/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5002—Partitioning blood components
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5094—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for blood cell populations
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56977—HLA or MHC typing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/96—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood or serum control standard
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2496/00—Reference solutions for assays of biological material
    • G01N2496/05—Reference solutions for assays of biological material containing blood cells or plasma
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/101666—Particle count or volume standard or control [e.g., platelet count standards, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Ecology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
NO960049A 1993-07-05 1996-01-05 Fremstilling og stabilisering av celler NO960049L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB939313962A GB9313962D0 (en) 1993-07-05 1993-07-05 Preparation and stabilisation of leucocytes
GB939315871A GB9315871D0 (en) 1993-07-05 1993-07-20 Preparation and stabilisation of leucocytes
GB9406698A GB9406698D0 (en) 1994-04-05 1994-04-05 Preparation and stabilisation of cell suspensions
PCT/EP1994/002189 WO1995001796A1 (en) 1993-07-05 1994-07-05 Preparation and stabilisation of cells

Publications (2)

Publication Number Publication Date
NO960049D0 NO960049D0 (no) 1996-01-05
NO960049L true NO960049L (no) 1996-03-05

Family

ID=27266764

Family Applications (1)

Application Number Title Priority Date Filing Date
NO960049A NO960049L (no) 1993-07-05 1996-01-05 Fremstilling og stabilisering av celler

Country Status (14)

Country Link
US (2) US6197540B1 (de)
EP (1) EP0708649B1 (de)
JP (1) JPH09503051A (de)
AT (1) ATE241368T1 (de)
AU (2) AU700699B2 (de)
BR (1) BR9407003A (de)
CA (1) CA2166729A1 (de)
DE (2) DE69432751T2 (de)
ES (1) ES2197168T3 (de)
FI (1) FI960045A0 (de)
GB (1) GB2279653B (de)
NO (1) NO960049L (de)
NZ (1) NZ271318A (de)
WO (1) WO1995001796A1 (de)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR9407003A (pt) * 1993-07-05 1996-03-26 North Gen Hospital Nhs Trust Preparaçao e estabilizaçao de células
ATE170979T1 (de) * 1994-04-05 1998-09-15 North Gen Hospital Nhs Trust Herstellung und stabilisierung von zellsuspensionen
GB2313288B (en) * 1996-05-24 2000-07-12 North Gen Hospital Nhs Trust Specimen collection fluid
EP1182457A1 (de) * 2000-08-17 2002-02-27 Mallinckrodt Baker B.V. Verfahren und Reagens zur Analyse von Blutproben, im besonderen für tierärztliche Anwendungen
US6913932B2 (en) * 2002-08-23 2005-07-05 Beckman Coulter, Inc. Formaldehyde-ammonium salt complexes for the stabilization of blood cells
CA2445204C (en) * 2002-10-16 2014-08-12 Streck Laboratories, Inc. Method and device for collecting and preserving cells for analysis
US7267980B1 (en) 2003-04-04 2007-09-11 Research & Diagnostic Systems, Inc. Stabilizing solution for cells and tissues
US20050085028A1 (en) * 2003-10-21 2005-04-21 International Business Machines Corporation Method and structure to suppress external latch-up
CN100376669C (zh) * 2005-02-25 2008-03-26 深圳迈瑞生物医疗电子股份有限公司 生物红细胞体积长期稳定的处理方法
US20070015134A1 (en) * 2005-07-15 2007-01-18 Beckman Coulter, Inc. Quantitative stabilized cell reference control products and methods
US11111544B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
US9424392B2 (en) 2005-11-26 2016-08-23 Natera, Inc. System and method for cleaning noisy genetic data from target individuals using genetic data from genetically related individuals
US11111543B2 (en) 2005-07-29 2021-09-07 Natera, Inc. System and method for cleaning noisy genetic data and determining chromosome copy number
CA2730191C (en) * 2008-07-11 2018-06-19 Secretary Of State For Health Stimulated cell standards
WO2010078194A1 (en) 2008-12-30 2010-07-08 Streck, Inc. Method for screening blood using a preservative that may be in a substantially solid state form
US11634747B2 (en) * 2009-01-21 2023-04-25 Streck Llc Preservation of fetal nucleic acids in maternal plasma
DK2398912T3 (en) 2009-02-18 2017-10-30 Streck Inc Conservation of cell-free nucleic acids
ES2571104T3 (es) * 2009-11-09 2016-05-24 Streck Inc Estabilización del ARN y extracción del ARN presente en células intactas dentro de una muestra de sangre
US12221653B2 (en) 2010-05-18 2025-02-11 Natera, Inc. Methods for simultaneous amplification of target loci
CA3037126C (en) 2010-05-18 2023-09-12 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11408031B2 (en) 2010-05-18 2022-08-09 Natera, Inc. Methods for non-invasive prenatal paternity testing
US11326208B2 (en) 2010-05-18 2022-05-10 Natera, Inc. Methods for nested PCR amplification of cell-free DNA
US11332785B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11322224B2 (en) 2010-05-18 2022-05-03 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11939634B2 (en) 2010-05-18 2024-03-26 Natera, Inc. Methods for simultaneous amplification of target loci
US11332793B2 (en) 2010-05-18 2022-05-17 Natera, Inc. Methods for simultaneous amplification of target loci
US10316362B2 (en) 2010-05-18 2019-06-11 Natera, Inc. Methods for simultaneous amplification of target loci
US12152275B2 (en) 2010-05-18 2024-11-26 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US11339429B2 (en) 2010-05-18 2022-05-24 Natera, Inc. Methods for non-invasive prenatal ploidy calling
US20190010543A1 (en) 2010-05-18 2019-01-10 Natera, Inc. Methods for simultaneous amplification of target loci
BR112013016193B1 (pt) 2010-12-22 2019-10-22 Natera, Inc. método ex vivo para determinar se um suposto pai é o pai biológico de um feto que está em gestação em uma gestante e relatório
BR112013020220B1 (pt) 2011-02-09 2020-03-17 Natera, Inc. Método para determinar o estado de ploidia de um cromossomo em um feto em gestação
US9956281B2 (en) 2011-05-04 2018-05-01 Streck, Inc. Inactivated virus compositions and methods of preparing such compositions
US20140100126A1 (en) 2012-08-17 2014-04-10 Natera, Inc. Method for Non-Invasive Prenatal Testing Using Parental Mosaicism Data
ES2938048T3 (es) 2013-07-24 2023-04-04 Streck Llc Composiciones y procedimientos para estabilizar las células tumorales circulantes
CA2945962C (en) 2014-04-21 2023-08-29 Natera, Inc. Detecting mutations and ploidy in chromosomal segments
US20180173845A1 (en) 2014-06-05 2018-06-21 Natera, Inc. Systems and Methods for Detection of Aneuploidy
US11168351B2 (en) 2015-03-05 2021-11-09 Streck, Inc. Stabilization of nucleic acids in urine
WO2016183106A1 (en) 2015-05-11 2016-11-17 Natera, Inc. Methods and compositions for determining ploidy
US20170145475A1 (en) 2015-11-20 2017-05-25 Streck, Inc. Single spin process for blood plasma separation and plasma composition including preservative
ES2913468T3 (es) 2016-04-15 2022-06-02 Natera Inc Métodos para la detección del cáncer de pulmón.
WO2018022991A1 (en) 2016-07-29 2018-02-01 Streck, Inc. Suspension composition for hematology analysis control
US11485996B2 (en) 2016-10-04 2022-11-01 Natera, Inc. Methods for characterizing copy number variation using proximity-litigation sequencing
GB201618485D0 (en) 2016-11-02 2016-12-14 Ucl Business Plc Method of detecting tumour recurrence
US10011870B2 (en) 2016-12-07 2018-07-03 Natera, Inc. Compositions and methods for identifying nucleic acid molecules
EP3571314B1 (de) 2017-01-22 2023-12-20 Chryos, LLC Zusammensetzung und verfahren zur verwendung davon zur konservierung von zellen zur analyse
US12378543B2 (en) 2017-10-19 2025-08-05 Streck Llc Compositions for hemolysis and coagulation regulation and stabilization of extracellular vesicles
CA3085933A1 (en) 2017-12-14 2019-06-20 Tai Diagnostics, Inc. Assessing graft suitability for transplantation
EP3781714B1 (de) 2018-04-14 2026-01-07 Natera, Inc. Verfahren zur krebserkennung und -überwachung durch personalisierte detektion zirkulierender tumor-dna
WO2019210306A1 (en) * 2018-04-27 2019-10-31 Momenta Pharmaceuticals , Inc. Blood preparation
US12234509B2 (en) 2018-07-03 2025-02-25 Natera, Inc. Methods for detection of donor-derived cell-free DNA
WO2020247263A1 (en) 2019-06-06 2020-12-10 Natera, Inc. Methods for detecting immune cell dna and monitoring immune system
CN113325171B (zh) * 2021-08-02 2021-12-21 天津康博尔生物基因技术有限公司 检测人体红细胞叶酸含量的试剂盒、检测方法及用途

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068862B (de) 1957-05-03 1959-11-12 Penicillin-Gesellschaft Dauelsberg a Co., Göttingen Verfahren zur Verlängerung der Haltbarkeit von Blutkonserven
DE1147004B (de) * 1959-10-16 1963-04-11 Dr Med Herbert Fischer Verfahren zur Konservierung von lebenden menschlichen oder tierischen Zellpraeparaten, insbesondere von Blut und Blutbestandteilen
CA933092A (en) * 1969-04-10 1973-09-04 V. Collins Zeola Method of prolonging the viability of lymphocytes
FR2202688B1 (de) 1972-10-17 1977-04-15 Cepbepe
US4045488A (en) 1974-11-06 1977-08-30 Pfizer Inc. Aminophenyltetralin compounds
IT1065125B (it) 1975-08-20 1985-02-25 Boehringer Mannheim Gmbh Processo per mantenere costante l attivita di fosfatasi alcalina e siero di controllo contenente tale fosfatasi
DE2551208C3 (de) * 1975-11-14 1981-05-27 Behringwerke Ag, 3550 Marburg Verfahren zur Herstellung einer stabilen Erythrozyten-Präparation
US4040785A (en) 1976-10-18 1977-08-09 Technicon Instruments Corporation Lysable blood preservative composition
US4152208A (en) * 1977-03-29 1979-05-01 Hoffmann-La Roche Inc. Stabilized leucocytes
DE2828820A1 (de) * 1977-08-01 1979-02-08 Warner Lambert Co Verfahren zur herstellung einer stabilen blutplaettchensuspension und nach dem verfahren erhaltene stabile blutplaettchensuspension
US4302355A (en) * 1977-08-01 1981-11-24 Warner-Lambert Company Platelet reference control
US4324687A (en) 1979-02-15 1982-04-13 Louderback Allan Lee Blood biochemistry control standard
DE2949824A1 (de) * 1979-12-12 1981-07-02 Marianne Dr. 5000 Köln Sehrbundt Verfahren zur stabilisierung von lymphozyten/thrombozytennmischsuspensionen
US4346018A (en) 1980-06-16 1982-08-24 Coulter Electronics, Inc. Multi-purpose blood diluent and lysing agent for differential determination of lymphoid-myeloid population of leukocytes
US4405719A (en) 1981-05-29 1983-09-20 Coulter Electronics, Inc. Method of stabilizing platelets for determining multiple platelet parameters in reference control and calibrator compositions; diluents therefor; and combination stabilization procedures
US4704352A (en) * 1985-06-25 1987-11-03 Baxter Travenol Laboratories, Inc. L-ascorbate-2-phosphate salts in blood cell storage
DE3663453D1 (en) 1985-08-08 1989-06-29 Eberhard Liss Method for inhilition of the reduction of the glucose-content in blood
US4675185A (en) * 1985-12-06 1987-06-23 Baxter Travenol Laboratories, Inc. Solution for stabilizing red blood cells during storage
US4729959A (en) 1986-02-24 1988-03-08 Streck Laboratories, Inc. Glucose reference control for glucose test strips
US4806343A (en) 1986-03-13 1989-02-21 University Of Southwestern Louisiana Cryogenic protectant for proteins
IT1188132B (it) * 1986-05-07 1987-12-30 Fameccanica Spa Procedimento e dispositivo per la produzione di film perforati particolarmente film perforati di materiale plastico per articoli igienico sanitari
US5250438A (en) 1990-05-09 1993-10-05 Streck Laboratories, Inc. Method for differential determination of white blood cells using diazolidinyl urea to stabilize white blood cells
SU1767436A1 (ru) 1990-05-22 1992-10-07 Черновицкий Государственный Университет Способ определени глюкозы в крови
US5260048A (en) 1991-05-08 1993-11-09 Streck Laboratories, Inc. Tissue fixative solution and method
US5270208A (en) * 1991-05-09 1993-12-14 Streck Laboratories, Inc. White blood cell hematology control
JPH0820452B2 (ja) 1991-12-16 1996-03-04 株式会社いかがく 血液中糖類の微生物による消費阻止方法
US5422277A (en) * 1992-03-27 1995-06-06 Ortho Diagnostic Systems Inc. Cell fixative composition and method of staining cells without destroying the cell surface
WO1993021928A1 (en) 1992-04-24 1993-11-11 Streck Laboratories, Inc. Liquid glucose control solution and process of making the same
US5407794A (en) * 1992-09-08 1995-04-18 Cytocolor Inc. Oxazine stained lymphocytes and method
DE69333586T2 (de) 1992-09-10 2005-09-01 Streck Laboratories, Inc., Omaha Verfahren und zusammensetzung zur konservierung von antigenen und verfahren zur verwendung von durch selbiges verfahren hergestellten zytologischem material
FR2705359B1 (fr) * 1993-05-19 1995-08-18 Immunotech Sa Méthode de protection des cellules leucocytaires, composition protectrice, composition de sang protégée, et méthode d'analyse sanguine.
BR9407003A (pt) 1993-07-05 1996-03-26 North Gen Hospital Nhs Trust Preparaçao e estabilizaçao de células
ATE170979T1 (de) 1994-04-05 1998-09-15 North Gen Hospital Nhs Trust Herstellung und stabilisierung von zellsuspensionen

Also Published As

Publication number Publication date
BR9407003A (pt) 1996-03-26
FI960045L (fi) 1996-01-05
DE708649T1 (de) 2001-09-20
US6197540B1 (en) 2001-03-06
DE69432751D1 (de) 2003-07-03
CA2166729A1 (en) 1995-01-19
ES2197168T3 (es) 2004-01-01
AU7490994A (en) 1995-02-06
JPH09503051A (ja) 1997-03-25
GB9413558D0 (en) 1994-08-24
AU700699B2 (en) 1999-01-14
ATE241368T1 (de) 2003-06-15
FI960045A7 (fi) 1996-01-05
FI960045A0 (fi) 1996-01-05
GB2279653B (en) 1998-02-11
EP0708649B1 (de) 2003-05-28
US6197539B1 (en) 2001-03-06
AU4441096A (en) 1996-06-06
GB2279653A (en) 1995-01-11
NO960049D0 (no) 1996-01-05
DE69432751T2 (de) 2004-04-29
NZ271318A (en) 1998-08-26
WO1995001796A1 (en) 1995-01-19
EP0708649A1 (de) 1996-05-01

Similar Documents

Publication Publication Date Title
NO960049L (no) Fremstilling og stabilisering av celler
ES2122589T3 (es) Preparacion y estabilizacion de suspensiones celulares.
AU6056194A (en) Substituted mono- and bipyridylmethylpyridones
AU3154295A (en) Method for preserving cells, and uses of said method
AU7650294A (en) Aminocyclohexylesters and uses thereof
DK473987A (da) Fremgangsmaade til kontinuert produktion af et oensket heterologt protein i en eukaryotisk vaertcelle, vektor, som tilfoerer denne evne, og celler transformeret med vektoren
HU905605D0 (en) Substituted imidazoles
CA2093428A1 (en) Methods for Treating Cotton-Containing Fabrics with Cellulase
CA2148928A1 (en) Pharmacologically active pyridine derivatives and processes for the preparation thereof
IE800102L (en) N-benzylimidazoles
WO1996003515A3 (en) Surface expression of enzyme in gene directed prodrug therapy
AU8097491A (en) Benzoic acid substituted derivatives having cardiovascular activity
EP0342034A3 (de) Verfahren zur Haarfärbung durch die aufeinanderfolgende Applikation einer Metallionen enthaltenden Zusammensetzung und einer eine 5,6-dihydroxy-2-karbonsäure enthaltenden Zusammensetzung
EP0350012A3 (de) Antivirale Zusammensetzung
AU2844889A (en) Method for suppressing the growth of normal and cancer cells
EP0227450A3 (de) Substituierte 5,6-Dialkoxychinazolin-Derivate
CA2227241A1 (en) Method of decreasing radiation or radio-mimetic chemotherapy for hematopoietic pluripotent cell engraftment
AU7938294A (en) Method for controlled modification of enzymes, enzymes modified in this way and the use of such enzymes
AU7226391A (en) Method of restoring normal growth, weight gain or lean body mass in patients with glucocorticoid excess
BR9100221A (pt) Composto;metodo para o tratamento de hipertensao,falha cardiaca congestiva ou glaucoma em um mamifero;e composicao farmaceutica
AU1095595A (en) Gene therapy vector for the treatment of low or defective red blood cell production
WO2003033723A3 (en) Vectors for expressing multiple transgenes
AU673414B2 (en) Cathodic active material composition for dry cells, method for preparing the same, and alkaline battery
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
EP0350887A3 (de) Serum-freies Medium und Verfahren zur Züchtung von Säugetierzellen

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application